Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
Gamestop, FST Corp, Merck, UPS, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Measles Cases Exceed 320 in Texas; DC Confirms Case in Amtrak
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment
2 billion USD! Heng Rui has authorized the Lp(a) small molecule inhibitor to Merck | Quick read announcement.
① Jiangsu Hengrui Pharmaceuticals will receive an upfront payment of 0.2 billion USD and is eligible for milestone payments of up to 1.77 billion USD as well as a commission for sales upon approval; ② HRS-5346, as an oral small molecule Lp(a) inhibitor, has good potential in the fields of chronic diseases and cardiovascular health; ③ In October of last year, CSPC PHARMA also entered into a licensing cooperation with AstraZeneca for small molecule Lp(a) inhibitors.
Alkermes Spinoff Mural Plunges on Plans to Halt Ovarian Cancer Trial
Trump to Nominate Acting CDC Director Monarez to Lead Agency - Report